RNAZ Stock Summary and Trading Ideas (Transcode Therapeutics | NASDAQ:RNAZ)

TransCode Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of RNA-based therapeutics and immuno-oncology treatments for cancer. The company's lead candidate, TTX-MC138, targets microRNA-10b and has completed a Phase 1a clinical trial, while it is also advancing additional product candidates, including a cancer vaccine and an oncolytic immunotherapy platform.

Transcode Therapeutics trades on the NASDAQ stock market under the symbol RNAZ.

As of October 7, 2026, RNAZ stock price declined to $1.76 with 26,348 million shares trading.

RNAZ has a beta of 0.09, meaning it tends to be less sensitive to market movements. RNAZ has a correlation of 0.00 to the broad based SPY ETF.

RNAZ has a market cap of $1.86 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, RNAZ traded as high as $19,588.82 and as low as $1.52.

The top ETF exchange traded funds that RNAZ belongs to (by Net Assets): VXF.

RNAZ has underperformed the market in the last year with a price return of -85.1% while the SPY ETF gained +16.9%. RNAZ has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -77.3% and -0.6%, respectively, while the SPY returned +3.7% and +0.5%, respectively.

RNAZ support price is $1.61 and resistance is $1.95 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RNAZ shares will trade within this expected range on the day.